DAV0602 is a new drug entity for increasing the cytotoxic activity of other anti-cancer drugs, notably temezolamide (used for glioblastomas) and platin derivatives.
 

About Glioblastoma

Glioblastoma is a relatively rare disease with a high mortality rate (5 year survival rate is <5%) characterised by huge unmet medical need. Treatment options include surgical resection, radiotherapy, and drug therapy. Temozolamide (Temodar®, approved in 1999), a cytotoxic compound is the only widely used drug to treat glioblastomas.

However, in general, treatment options for glioblastomas are limited. Main reasons are poor penetration across the blood-brain barrier, immune escape of glioblastoma cells, rapid development of tumor resistance to cytotoxics and aggressive nature of brain cancer. In contrast, the investigational drug DAV0602 is characterized by its natural occurrence in the cell, its penetration into the brain and its ability to potentiate anti-cancer effects of Temodar®.
Another potential application would be reduction of cisplatin-toxicity while maintaining efficacy.
 

Development Status

Preclinical studies using DAV0602 revealed consistent efficacy against glioblastoma cell lines, penetration into the brain leading to rapid and sustained drug levels and anti cancer effects via multiple cellular mechanisms. DAV0602 combines selective inherent cytotoxicity with cytoprotection and exhibits direct anti proliferative action via multiple cellular mechanism. DAV0602 can be developed both as oral tablet and i.v. infusion.
 

Intellectual Property Position

The product is covered by substance, use and indication patents that have been granted in EU (Austria, Belgium, Switzerland, Lichtenstein, Germany, Spain, France, UK, Greece, Italy, Portugal, Sweden, Turkey), Australia, Mexico and US; applied in Canada, Japan, Poland, China, Eurasia and Indonesia.

Contact for further product information